Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients - 20/04/21
, Yuanhui Yao c, Zishu Zhang d, Cong Ma d, Yilong Ma e, Chang Zhao e, Hua Xiang c, Hui Zhao f, Chuansheng Zheng g, Bin Xiong g, Haiping Li a, Qingyun Long h, Jun Zhou h, Chao Luo b, Hongyao Hu f, ⁎ Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 11 |
| Iconografia | 3 |
| Video | 0 |
| Altro | 0 |
Highlights |
• | In total patients, history of drink and largest nodule size≥7cm could independently predict worse ORR, and DEB-TACE predicted better OS, while largest nodule size≥7cm, Child-Pugh stage (B/C vs. A), ALB abnormal, ALP abnormal or AFP abnormal predicted worse survival. |
• | In DEB-TACE group, previous cTACE and ANC abnormal were independent factors predicting worse ORR, and hepatic vein invasion, Child-Pugh stage (B/C vs. A) or AFP abnormal could independently predict poor survival. |
• | In cTACE group, largest nodule size≥7cm was an independent risk factor for predicting ORR, and multifocal disease as well as ALB abnormal predicted poor OS. |
Summary |
Background |
Transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients who are not suitable for surgical treatment. We aimed to investigate the treatment outcomes and comprehensive prognostic factors of CalliSpheres® microspheres (CSM) drug-eluting bead TACE (DEB-TACE) treatment and conventional TACE (cTACE) treatment in HCC patients.
Methods |
Three hundred and thirty-five HCC patients received DEB-TACE or cTACE treatment were consecutively enrolled in multi-center, retrospective cohort study. Treatment response was conducted at M1, M3 or M6 after treatment. Progression free survival (PFS) and overall survival (OS) were recorded. Thirty-seven baseline factors including demographic characteristics, clinical features, biochemical indexes and previous treatment histories were selected.
Results |
In total patients, history of drink and largest nodule size≥7cm independently predicted worse ORR, DEB-TACE predicted better OS, while largest nodule size≥7cm, increased Child-Pugh stage, ALB abnormal, ALP abnormal or AFP abnormal predicted worse survival. For DEB-TACE group, previous cTACE and ANC abnormal independently predicted worse ORR, and hepatic vein invasion, increased Child-Pugh stage or AFP abnormal independently predicted poor survival. For cTACE group, largest nodule size≥7cm independently predicted poor ORR, and multifocal disease as well as ALB abnormal predicted poor OS.
Conclusions |
History of drink, largest nodule size≥7cm, DEB-TACE, increased Child-Pugh stage, abnormal ALB, ALP or AFP are potential prognostic factors in total patients, previous cTACE and ANC abnormal, hepatic vein invasion, increased Child-Pugh stage or AFP abnormal are potential prognostic factors in DEB-TA group, and largest nodule size≥7cm, multifocal disease and ALB abnormal are potential prognostic factors in cTACE group.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Prognostic factors, Drug-eluting bead-transarterial chemoembolization, Conventional transarterial chemoembolization, Treatment response, Survival, Hepatocellular carcinoma
Abbreviations : HCC, CR, TACE, cTACE, DEB-TACE, CSM, HB, HC, ECOG, BCLC, WBC, RBC, ANC, Hb, PLT, ALB, TP, TBIL, TBA, ALT, AST, ALP, BCr, BUN, AFP, CEA, CA199, RT, DSA, CT, MRI, EPO, PVA, IV, M1, Mrecist, CR, PR, SD, PD, ORR, DCR, PFS, OS, RCT
Mappa
Vol 45 - N° 2
Articolo 101460- Marzo 2021 Ritorno al numero
Articolo precedente
- Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI)
- Jean Frédéric Blanc, Audrey Debaillon-Vesque, Gaël Roth, Jean Claude Barbare, Anne Sophie Baumann, Valérie Boige, Karim Boudjema, Mohamed Bouattour, Gilles Crehange, Barbara Dauvois, Thomas Decaens, François Dewaele, Olivier Farges, Boris Guiu, Antoine Hollebecque, Philippe Merle, Janick Selves, Thomas Aparicio, Isaac Ruiz, Olivier Bouché, on behalf of the Thésaurus National de Cancérologie Digestive (TNCD), Société Nationale Française de Gastroentérologie (SNFGE), Fédération Francophone de Cancérologie Digestive (FFCD), Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR), Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER), Société Française de Chirurgie Digestive (SFCD), Société Française d’Endoscopie Digestive (SFED), Société Française de Radiothérapie Oncologique (SFRO), Association Française pour l’Etude du Foie (AFEF)
- Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study
- Anthony Turpin, Thierry de Baere, Alexandra Heurgué, Karine Le Malicot, Isabelle Ollivier-Hourmand, Thierry Lecomte, Hervé Perrier, Julien Vergniol, David Sefrioui, Yves Rinaldi, Julien Edeline, Jean-Louis Jouve, Christine Silvain, Yves Becouarn, Barbara Dauvois, Mathieu Baconnier, Maryline Debette-Gratien, Gael Deplanque, Sébastien Dharancy, Côme Lepage, Mohamed Hebbar, PRODIGE 16 investigators Collaborators
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?